Our Mission: End Chronic Pain and Opioid Dependence
Chronic pain and opioid dependence represent two of the most urgent
health crises of our time, affecting millions of people and
straining healthcare systems worldwide. Current treatments are often
inadequate, leaving patients with limited options and vulnerable to
opioid misuse.
Neomera's mission is to change this reality. By harnessing
AI-powered drug discovery and advancing novel therapeutics, we aim
to provide solutions that restore quality of life while reducing
reliance on addictive treatments.
Neomera is co-founded by three Stanford graduates and serial
entrepreneurs, bringing together more than a decade of experience in
drug development. Our advisory board adds over decades of pioneering
expertise in pain research and therapeutics.
Together, this combination of entrepreneurial execution and
world-class scientific leadership uniquely positions Neomera to
tackle problems once considered impossible.
Our Platform: AI-Powered Solutions for Target Selectivity
Lack of selectivity is a persistent barrier in both traditional
laboratory discovery and contemporary AI-driven approaches,
preventing the development of safe and effective therapeutics for
many critical targets.
Neomera has developed a powerful platform to overcome one of the
most formidable challenges in drug discovery: achieving target
selectivity among closely related protein family members.
Our Lead Program: Dual NaV1.8/NaV1.9 Peptide Inhibitor for Chronic
Pain
The biology of NaV1.8 and NaV1.9 in acute and chronic pain is well
validated and extensively studied in published literature.
Our peptide inhibitor selectively blocks NaV1.8 and NaV1.9 channels,
which are predominantly expressed in peripheral nociceptive neurons
with minimal CNS presence. This peripheral selectivity enables
effective analgesia without central nervous system complications or
addiction liability, a critical advantage over opioids.
